It depends on the level of customization. For standard, off-the-shelf equipment, the baseline expectation is compliance with Good Manufacturing Practice (GMP) standards. This includes a comprehensive documentation package with design documents, operating manuals, and qualification protocols. Specific regulatory requirements, such as data integrity, audit trails, and compliance with 21 CFR Part 11 or EU Annex 11, must also be clearly addressed.

For partially or fully customized equipment, expectations are higher. End users look for a risk-based design approach aligned with GAMP 5 principles, full traceability from user requirements to testing protocols, and an integrated quality risk management process. OEMs must justify their design decisions, evaluate potential failure modes, and proactively collaborate with validation and quality teams. Full-service qualification covering DQ, IQ, OQ, and PQ support is often expected to streamline implementation.

In biotechnology operations—where precision, compliance, and system uptime are critical—AES provides comprehensive maintenance and service programs to ensure your equipment consistently delivers optimal performance. Our support extends asset life, minimizes downtime, and safeguards process integrity from R&D through to production.

Consider a mid-size bioproduction facility working on late-stage clinical material. When a valve unexpectedly failed, they didn’t have an emergency response contract or the part in stock. The result? A total batch loss and a five-week delay on a critical trial. “That kind of impact goes far beyond repair costs,” says Emily. “It affects timelines, team morale, even investor confidence.”

In highly regulated environments, delays can trigger a domino effect, pushing back validations, disrupting supply chains, and impacting patient access. With each hour of downtime, opportunity costs grow.

CMOs need flexible manufacturing solutions in order to support multiple clients with varying needs for their products. Single-use bioprocessing can help:

• Adapt quickly to differing batch sizes without major facility reconfigurations. This allows greater flexibility in production because traditional stainless-steel setups typically require modifications to accommodate different batch volumes. With single-use systems, production can scale seamlessly by swapping out bioreactors, tubing, and consumables as needed. This minimizes downtime and provides better support for multi-client workflows.
• Support multiple bioprocesses while reducing the risk of cross-contamination and batch failure. Stainless steel systems require extensive cleaning validation between runs, but single-use systems provide sterile components for each run, nearly eliminating any risk of contamination. This allows CMOs to run multiple client projects simultaneously, improving operational efficiency and enabling quicker product changeovers. 
• Reduced Downtime by eliminating the need for cleaning, sterilization, and validation processes. Stainless steel systems require CIP and SIP processes, followed by validation to guarantee compliance before the next run can start. Single-use systems use pre-sterilized and disposable components that allow quick transitions from one batch to the next while maintaining sterility and compliance.